Antibody Protein Sequencing Services2021-10-14T13:25:34-04:00

REmAb® Antibody Sequencing Service.

REmAb® can determine the amino acid sequence of your monoclonal antibodies with high-throughput, full coverage de novo protein sequencing. Complete. Accurate. Industry leading.

Established protein sequencing platform.

REmAb® is built on a strong foundation of over 20 years of mass spectrometry and bioinformatics expertise. We foster continuous innovation. Our patented protein chemistry protocols and proprietary big data machine learning algorithms facilitate novel discoveries, empowering our clients further their research faster and more confidently.

High-throughput, uncompromisingly accurate.

REmAb®’s core strength is its uncompromising accuracy. Thousands of overlapping peptides support the protein sequence, which is why we can confidently claim 100% accuracy. REmAb®’s fast and robust platform fuels trailblazing research worldwide.

Enabling and safeguarding discoveries.

A consistently reliable antibody is one of a kind. With REmAb®, researchers have the choice to use mAbs without being blind to protein sequence information – thereby safeguarding results for project continuance, patents, or regulatory approval.

How It Works.

The REmAb® workflow delivers a full coverage sequence with unparalleled accuracy, 100% of the time (see sample requirements below). Starting with only a small sample of protein, we conduct proprietary chemistry, LC-MS/MS proteomics and machine-learning driven sequencing.

Parameters.

Turn-around time

11+ samples, 4 weeks
2-10 samples, 3 weeks
1 sample, 2 weeks
Rush, 1 week

Requirements

Any species

Any isotype

100 μg of protein, >80% purity

Is your sample smaller or less pure?

Ask us
. We can often still get results.

Deliverables

The entire mAb sequence averaging 30X coverage per amino acid. Sample coverage view.

Independent review – sequences derived by proprietary bioinformatics and expert reviews.

Isobaric checks – all isobaric combinations are determined by WILD®.

REmAb® routinely facilitates novel discoveries, and strengthens antibody characterization. We’ve saved hundreds of hybridomas and contributed to dozens of papers and helped create products and patents worth millions of dollars.

We’re #1 in the world for de novo sequencing.

3000+ projects completed
100+ samples processing at any moment
100% satisfaction rate

Pricing.

List Price

$13000
  • Bulk Order Discounts Available
  • (Optional) +$1000 MATCHmAb™ **
  • (Optional) +$2000 Rush Order
  • (Optional) Recombinant Expression
  • Ask about add-ons for: non-antibody protein sequencing, intact mass analysis, PTM studies, etc.

Intro Offer

$4999
  • First Time Customers Only, IgG only.
  • (Optional) +$1000 MATCHmAb™ **
  • (Optional) +$2000 Rush Order
  • (Optional) Recombinant Expression
  • Ask about add-ons for: non-antibody protein sequencing, intact mass analysis, PTM studies, etc.

Received a lower quote? We’ll match or beat other prices.

** MATCHmAbTM can confirm the sequence of your expressed antibody matches the original.

“Rapid Novor was tasked with finding highly specific, high affinity antibodies against an important target- and they delivered powerful antibodies fit-for-purpose. Such antibodies are not easily obtained yet the Rapid Novor approach proved immediately successful, despite our time-constrained and stringent demands.”

Matt Pope, VP of Client Services, SISCAPA

“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”

Pavel Khrimian – Co-founder and CBO, Deka Biosciences

“The sequences have allowed us to have an “insurance policy” of sorts for critical proteins used in our various products.”

David Ankrapp, Senior Research Scientist, Neogen Corporations

Learn More.

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

DNA Sequencing vs Next Generation Protein Sequencing

The protein sequence is key to understanding the function of a protein target, and is critical to therapeutic and diagnostic development. This is particularly important for antibodies whose code diversity and glycosylation impact both function, and stability.

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 3000 antibodies and we are eager to help you.